GridAI Technologies Corp. (GRDX) - Total Liabilities

Latest as of March 2026: $20.47 Million USD

Based on the latest financial reports, GridAI Technologies Corp. (GRDX) has total liabilities worth $20.47 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GRDX shareholders equity momentum to track the company's year-over-year net asset growth rate.

GridAI Technologies Corp. - Total Liabilities Trend (2013–2025)

This chart illustrates how GridAI Technologies Corp.'s total liabilities have evolved over time, based on quarterly financial data. See GRDX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

GridAI Technologies Corp. Competitors by Total Liabilities

The table below lists competitors of GridAI Technologies Corp. ranked by their total liabilities.

Company Country Total Liabilities
Flap Kongre Toplanti Hizmetleri Otomotiv ve Turizm AS
IS:FLAP
Turkey TL156.49 Million
Sakthi Sugars Limited
NSE:SAKHTISUG
India Rs12.10 Billion
BeMetals Corp
V:BMET
Canada CA$12.91 Million
Watches Of Switzerland Group PLC
LSE:WOSG
UK GBX918.90 Million
Lumens Co. Ltd
KQ:038060
Korea ₩50.17 Billion
Elevation Oncology Inc
NASDAQ:ELEV
USA $35.49 Million
Vikas EcoTech Limited
NSE:VIKASECO
India Rs883.31 Million
SynCore Biotechnology Co Ltd
TWO:4192
Taiwan NT$14.88 Million

Liability Composition Analysis (2013–2025)

This chart breaks down GridAI Technologies Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is GridAI Technologies Corp. worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.91 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how GridAI Technologies Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for GridAI Technologies Corp. (2013–2025)

The table below shows the annual total liabilities of GridAI Technologies Corp. from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 $19.72 Million -28.57%
2024-12-31 $27.61 Million +741.55%
2023-12-31 $3.28 Million +21.60%
2022-12-31 $2.70 Million -86.25%
2021-12-31 $19.61 Million +26.00%
2020-12-31 $15.56 Million +263.18%
2019-12-31 $4.29 Million +43.07%
2018-12-31 $3.00 Million -21.56%
2017-12-31 $3.82 Million +7.86%
2016-12-31 $3.54 Million -65.67%
2015-12-31 $10.32 Million +162.42%
2014-12-31 $3.93 Million +318.49%
2013-12-31 $939.30K --

About GridAI Technologies Corp.

NASDAQ:GRDX USA Biotechnology
Market Cap
$21.67 Million
Market Cap Rank
#24811 Global
#5226 in USA
Share Price
$3.20
Change (1 day)
-16.23%
52-Week Range
$2.01 - $6.80
All Time High
$6.80
About

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in … Read more